{"groups":[{"description":"Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.","id":"FG000","title":"Temozolomide"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}